[Effects of preoperative systemic chemotherapy with respect to expressions of hormone receptors and HER2 / neu].
METHODS
Between August 2003 and January 2008, 35 patients with primary breast cancer received preoperative systemic chemotherapy(PSC).


METHODS
The subjects were divided into 4 groups based on the expressions of ER, PgR, and HER2: luminal A and B, HER2, and basal-like groups. FEC75 followed by docetaxel was administered preoperatively. However, a regimen with trastuzumab was employed after 2006.


RESULTS
The subjects consisted of 1 male and 34 females, with a mean age of 56.0 years. In 65.7% of these, axillar lymph node metastasis was detected before surgery: 13 patients in the luminal A, 4 in the luminal B, 13 in the HER2, and 5 in the basal-like groups. A clinical complete response(cCR)was achieved in 25.7% of the patients, and a partial response in 62.9%; the response rate was 88.6%. Pathologically, the grade was evaluated as 3 in 14.3% of the patients and 2 in 48.6%. In the basal-like and HER2 groups, the cCR and pCR rates were higher than those in the luminal groups. Combination therapy with trastuzumab was not effective in the HER2 or luminal B group.


CONCLUSIONS
This simple classification method may be useful for predicting the effects of PSC.
Ohta
Kouji
K
Dept. of Surgery, Fukui Prefectural Hospital, Japan.
Ito
Yoshitaka
Y
Miyanaga
Tamon
T
Dohden
Kenji
K
Hayashi
Hiroyuki
H
Hattori
Masakazu
M
Hosokawa
Osamu
O
Takeda
Takayuki
T
Kaizaki
Yasuharu
Y
Kiya
Tomoe
T
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab